Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue: +93.9%
EPS: −120.0%
Free cash flow: +13.4%
Total debt: +57.4%

Quarter to June 2026, against a year earlier

Revenue growth 3 yrs

8.55 0.54 +6.74%

Follow IBRX

Alert me

Market cap: $8.5B
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 4/9
Altman Z: −10.16
Beneish M: 4.57
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

ImmunityBio, Inc. 10-Q filed Nov 12, 2024

Fiscal Q3 2024 · Period ended Sep 30, 2024 · Filed Nov 12, 2024 · accepted 7:30 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov